Physician profile
Francesca Luppert
NPI 1538600390
$4,884.65
in general payments reported to CMS, 2019-2025
38 companies · $1,729 in 2025
The $1,729 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $99.93 · 2023: $1,220 · 2024: $1,836 · 2025: $1,729.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,690 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,689.73 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $681.73 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $451.73 | 2023-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $417.58 | 2023-2025 | Jardiance, Mounjaro, Zepbound |
| Sanofi-Aventis U.S. LLC | $373.32 | 2021-2025 | |
| Inspire Medical Systems, INC. | $337.37 | 2024-2025 | Inspire |
| Astellas Pharma US INC | $270.70 | 2023-2025 | Veozah, Myrbetriq |
| Novo Nordisk INC | $234.13 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $212.38 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $212.38 | 2023-2025 | Jardiance |
| Corcept Therapeutics | $175.70 | 2025 | Korlym |
| Corium, LLC | $147.28 | 2023-2024 | Azstarys |
| Bayer Healthcare Pharmaceuticals INC. | $130.20 | 2023-2025 | |
| Glaxosmithkline, LLC. | $116.66 | 2023-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Axsome Therapeutics, INC. | $112.31 | 2024-2025 | Auvelity |
| Amgen INC. | $108.08 | 2024 | Otezla, Repatha |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $106.31 | 2023-2025 | Rexulti |
| Dexcom, INC. | $98.94 | 2024-2025 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $75.68 | 2023-2025 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $58.80 | 2023-2024 | Xifaxan, Trulance |
| Halozyme INC | $58.67 | 2023 | |
| Dynavax Technologies Corporation | $51.40 | 2024-2025 | Heplisav-B |
| Novartis Pharmaceuticals Corporation | $49.66 | 2025 | |
| Ironshore Pharmaceuticals INC. | $45.93 | 2024 | |
| Tolmar, INC. | $43.82 | 2023-2025 | Jatenzo |
| Lundbeck LLC | $36.23 | 2025 | Vyepti, Rexulti |
| Abbott Laboratories | $34.43 | 2023 | Freestyle Libre |
| Stryker Corporation | $28.33 | 2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Olympus America INC. | $25.57 | 2023 | Spiration Valve System |
| Tris Pharma INC | $24.96 | 2023 | Quillivant, Dyanavel Xr, Quillichew Er |
| Boston Scientific Corporation | $23.51 | 2025 | Watchman Flx |
| Seqirus USA INC | $21.51 | 2025 | Flucelvax, Fluad |
| Antares Pharma, INC. | $18.81 | 2023 | Tlando, Xyosted, Nocdurna |
| Globus Medical, INC. | $18.07 | 2025 | Senza |
| Sanofi Pasteur INC. | $17.88 | 2025 | |
| Phathom Pharmaceuticals, INC. | $17.29 | 2025 | Voquezna |
| Ibsa Pharma INC. | $17.10 | 2023 | Tirosint, Licart |
| Medtronic, INC. | $15.42 | 2025 | Inceptiv |
| Xeris Pharmaceuticals, INC. | $14.78 | 2025 | Gvoke Hypopen |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Francesca Luppert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.